Enclosed please find the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025. Kindly take the same on record.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics reported its Q1 FY26 results with a standalone net loss of Rs. 214.30 lakhs, wider than the Rs. 140.73 lakh loss in the same quarter last year. Standalone revenue from operations rose marginally to Rs. 877.49 lakhs (vs Rs. 862.63 lakhs in Q1 FY25), while total expenses climbed to Rs. 1,097.91 lakhs from Rs. 1,010.56 lakhs, driven by higher employee and other costs. On a consolidated basis, the company posted a net loss of Rs. 64.07 lakhs, improving from a Rs. 412.88 lakh loss in Q4 FY25 but still in the red. Consolidated revenue from operations was approximately Rs. 3,750.51 lakhs, showing strong year-on-year growth. The statutory auditor (MSKA & Associates) issued a clean limited review report with no qualifications.
Shareholders should note that the company continues to report quarterly losses, with standalone losses worsening year-on-year despite stable revenue, indicating margin pressure. The narrowing consolidated loss is a positive signal, but sustained profitability remains a key concern for the stock.